Inhibikase Therapeutics, Inc. - The 201 Trial
The 201 Clinical Trial For Patients With Untreated Parkinson’s Disease
The 201 Clinical Trial is a trial that will explore whether a novel drug, Risvodetinib (IkT-148009), can slow or halt progression of Parkinson’s disease. The trial will also evaluate whether Risvodetinib (IkT-148009) can partially or completely restore lost function.
Study assessments, testing and medication are provided at no cost to participants. Financial support for travel to and from trial sites may be available.